Advertisement: Bradfield Centre mid
Advertisement: Cambridge Network
Advertisement: Lynch Wood Park
ARM Innovation Hub
Advertisement: Bridge Fibre mid
Advertisement: Mogrify mid banner
Barr Ellison Solicitors – commercial property
RealVNC mid-banner general
Advertisement: RSM
Advertisement EY mid banner
RealVNC mid banner careers
Advertisement Cambridge China Centre
Mid banner advertisement: BDO
Advertisement: CBM
1 May, 2019 - 20:53 By Tony Quested

Cambridge life science trio to storm Wall Street in $1/4 billion NASDAQ IPO surge

Nobel Prize winner Sir Greg Winter of Bicycle Therapeutics

Cambridge life science pioneer Bicycle Therapeutics is targeting an $86 million IPO on the US technology market NASDAQ – leading an unprecedented charge to Wall Street for life science companies in the UK’s leading life science cluster.

Business Weekly has been told by an informed source that Cambridge duo F-star and Kymab – both in the antibodies arena – intend to follow Bicycle to NASDAQ floats for roughly similar valuations.

For some while it has been a question which of the supercharged trio, all based on the Babraham Research Campus, would break cover first.

Bicycle is developing a new class of small, chemically synthesised medicines – called Bicycles – targeting cancers and other diseases. The company’s platform is based on the monoclonal antibodies science conducted by Sir Greg Winter, recently honoured as a Nobel Prize winner, and Professor Christian Heinis. The business is headed by ex-Pfizer research leader Kevin Lee.

Bicycle has research collaborations with AstraZeneca in respiratory, cardiovascular and metabolic disease, Bioverativ in non-malignant haematology indications, including haemophilia, and with Oxurion in ophthalmology.

Cambridge Innovation Capital, a patient capital fund principally backing hi-tech and biotech companies spinning out of Cambridge University, stands to receive a bumper dividend from a Bicycle exit.

Bicycle has not made any official comment on the NASDAQ IPO or issued any publicity but has pointed Business Weekly to sources confirming the move.

An influential inside-track life science entrepreneur told Business Weekly that F-star and Kymab are tipped to follow the lucrative trail to New York.

F-star develops genuine monoclonal bispecific antibodies that can bind two different targets at the same time, for use as 2-in-1 drugs.

Kymab rapidly develops broad diversity, high-quality human antibodies for treating challenging diseases.

Bicycle’s NASDAQ sortie would be the first life science IPO either side of the Atlantic so far in 2019. Cambridge already has cannabis-based medicines trailblazer GW Pharmaceuticals  thriving and raising mega-money on NASDAQ but this latest move would be unprecedented for the UK, let alone the Cambridge, biotech community, in terms of numbers and potential payback.

Newsletter Subscription

Stay informed of the latest news and features